Patent ID: 9707285
Date: 2017-07-18
CPC Classifications: A61K,A61P,C12N

Claim:
1. A method of treating a target cancer in a mammal comprising intravenously administering to the mammal an oncolytic rhabdoviral vector selected from a vesicular stomatitis virus (VSV) and a Maraba virus to which the mammal is naïve, wherein said oncolytic rhabdoviral vector expresses a natural tumour antigen associated with the target cancer and to which the mammal has a pre-existing immunity established by vaccinating the mammal with an adenoviral vector expressing the tumor antigen prior to administration of the oncolytic rhabdoviral vector, wherein said oncolytic rhabdoviral vector is replicating following administration and exhibits oncolytic activity against the target cancer cells, wherein the oncolytic rhabdoviral vector induces an anti-tumoral immune response in the mammal against the target cancer cells which is at least twice the anti-tumoral immune response against the target cancer cells induced by the oncolytic rhabdoviral vector when administered non-intravenously as assessed by determining the quantity of CD8+ T cells present in a sample isolated from the mammal that specifically react with said tumour antigen, and wherein the oncolytic rhabdoviral vector induces an anti-tumoral immune response in the mammal against the target cancer cells that is greater than an immune response in the mammal against the oncolytic rhabdoviral vector.